In the published research, Caltech and Children's Hospital Los Angeles investigators created a mouse model of Ewing's sarcoma that mimics the tumor localizations in humans and also provides for simultaneous, real-time bioluminescence imaging of the disseminated tumors by using human Ewing's sarcoma cells engineered to express luciferase.
Ewings Sarcoma Diagnosis - Beware of inense thigh pain
August 6, 2005 10:58
John Grossfeld was always fastidious about his health. He ran. He ate well. He didn't smoke. But two years ago, an intense pain in his right thigh proved to be the site of a large tumor spawned by Ewing's sarcoma, a rare form of bone cancer.... Blessed by caring community BY COLLIN NASH STAFF WRITER
MIT engineers an anti-cancer smart bomb
July 27, 2005 11:00
MIT engineers an anti-cancer smart bomb: Imagine a cancer drug that can burrow into a tumor, seal the exits and detonate a lethal dose of anti-cancer toxins, all while leaving healthy cells unscathed. MIT researchers have designed a nanoparticle to do just that. PhysOrg, Wed, 27 Jul 2005 10:33 AM PDT
Lawsuits for failure to diagnose Ewings Sarcoma - One person's story
July 19, 2005 11:02
Parker Jensen Lawsuit Raises New Questions: new lawsuit raises questions about Parker Jensen's diagnosis and treatment for the rare cancer called Ewing's Sarcoma. Parker's parents are suing the state, Intermountain Health Care, several doctors and others who worked on his case. That legal battle no doubt will focus heavily on several key medical issues.
Nanomaterials Used in Possible Cancer Cure
May 9, 2005 08:00
Slashdot, Sun, 08 May 2005 9:11 PM PDT
Moiche writes "Medical researchers at CalTech and the Children's Hospital in Los Angeles have successfully inhibited cancer growth in mice by wrapping engineered RNA in nanomaterials and introducing them into the bloodstream. Two polymers and a special coating allow the therapeutic RNA to enter the cancer cell and release the therapeutic RNA payload. The new technique has slowed or prevented the growth of cancer...
Novel gene-silencing nanoparticles shown to inhibit Ewing's sarcoma. A novel delivery system that transports gene silencing nanoparticles into tumor cells has been shown to inhibit Ewing's sarcoma in an animal model of the disease.
Nanoparticles Silence Childhood Cancer. Nanoparticles have been used to silence growth-promoting genes in a type of cancer called Ewing's sarcoma that affects children. Shown to work in an animal model of the disease, the Trojan horse approach utilizes a protein called transferrin that normally delivers iron into cells.
Sweet nanoparticles successfully deliver drugs to mouse tumours.
Five-year-old shows courage in battling Ewing's Sarcoma
May 9, 2005 06:44
The Courier, Fri, 29 Apr 2005 12:44 PM PDT
Strength can be measured in many ways. Five-year old Jazlyn Fergusons courage and mental and physical toughness has truly manifested during the last several months. She has inspired her family and friends by keeping an upbeat attitude as she battles Ewings' Sarcoma, a form of bone cancer.
Erin Clancy still was undergoing cancer treatments when she spoke at last year's Relay of Life in Riverside Park.
April 27, 2005 06:46
It wasn't easy. Clancy had both chemo and radiation therapies for Ewing's sarcoma, a rare bone cancer that mainly occurs in children and young adults. But she said she got through by making light of things and having her family's constant support.
"You can never give up on yourself," she said. "You keep dreaming."
Arrowhead Subsidiary Successful in Small Animal Studies for Anti-Cancer Compound IT-101
April 22, 2005 08:02
Business Wire via Yahoo! Finance, Wed, 20 Apr 2005 4:00 AM PDT
Arrowhead Research Corporation announced today that its majority-owned subsidiary, Insert Therapeutics, has released data demonstrating effective anti-cancer results in animal studies of its lead product, IT-101, against various cancers, including pancreatic cancer, colon cancer, breast cancer, lung cancer, and Ewing's Sarcoma, a cancer primarily affecting children and young adults.
Arrowhead Research Corp.'s (ARWR) anti-cancer compound demonstrated effectiveness in animal studies. Insert Therapeutics, Inc. Chief Scientific Officer, Thomas Schluep, Sc.D., presented data today demonstrating the improved biodistribution and preclinical efficacy in vivo of its lead anticancer compound, IT-101. Insert Therapeutics Describes In Vivo Performance and Versatility of Lead Anticancer Compound; Preclinical Results announced.
New options for children with bone cancer
April 21, 2005 06:49
The prognosis for children with bone cancer has greatly improved throughout the years. For example, Jenna Keen is a very active 13-year-old. When she was four, she was diagnosed with Ewing's Sarcoma in her leg.
A novel delivery system that transports gene silencing nanoparticles into tumor cells has been shown to inhibit Ewing's sarcoma in an animal model of the disease.
April 20, 2005 06:47
A protein called transferrin that normally delivers iron into cells is modified to also smuggle into tumor cells siRNA (short interfering RNA) encased in nano-sized sugar polymers. The siRNA was designed to target a specific growth-promoting gene called EWS-FLI1 that's active only in Ewing's sarcoma tumors.
To test their new delivery system, the scientists targeted tumor cells from the patients of Ewing's sarcoma, a rare and often deadly bone cancer that generally strikes young adults. Despite aggressive therapy, about 40 percent of patients with Ewing's family tumors and 95 percent with metastases die as a result of their disease.
Scientists now recognize that Ewing's sarcoma results when two chromosomes break and trade their genetic content in what's technically called a "translocation," activating the oncogene EWS-FLI1 which triggers the tumor growth characteristic for this cancer.
The scientists then tried their novel technology in laboratory mice grafted with human Ewing's sarcoma tumors. Following three consecutive days of treatment, the scientists observed strong, but transient, inhibition of tumor growth.
Future experiments will combine the novel delivery system with small molecular anti-tumor agents, with hopes of creating a new and effective way to treat Ewing's sarcoma and other tumors in the clinic.